HUE044292T2 - Eljárások és készítmények aeroszolok elõállítására - Google Patents

Eljárások és készítmények aeroszolok elõállítására

Info

Publication number
HUE044292T2
HUE044292T2 HUE11705486A HUE044292T2 HU E044292 T2 HUE044292 T2 HU E044292T2 HU E11705486 A HUE11705486 A HU E11705486A HU E044292 T2 HUE044292 T2 HU E044292T2
Authority
HU
Hungary
Prior art keywords
aerosols
compositions
preparation
methods
Prior art date
Application number
Other languages
English (en)
Inventor
Erik Depla
Mauro Sergi
Peter Casteels
Original Assignee
Ablynx Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ablynx Nv filed Critical Ablynx Nv
Publication of HUE044292T2 publication Critical patent/HUE044292T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HUE11705486 2010-02-11 2011-02-11 Eljárások és készítmények aeroszolok elõállítására HUE044292T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30344710P 2010-02-11 2010-02-11
US201061426610P 2010-12-23 2010-12-23

Publications (1)

Publication Number Publication Date
HUE044292T2 true HUE044292T2 (hu) 2019-10-28

Family

ID=43899571

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE11705486 HUE044292T2 (hu) 2010-02-11 2011-02-11 Eljárások és készítmények aeroszolok elõállítására

Country Status (17)

Country Link
US (3) US9713589B2 (hu)
EP (2) EP2533761B1 (hu)
JP (3) JP5951508B2 (hu)
CN (2) CN102753148B (hu)
AU (1) AU2011214299B2 (hu)
CA (1) CA2787718C (hu)
CY (1) CY1122634T1 (hu)
DK (1) DK2533761T3 (hu)
ES (2) ES2931330T3 (hu)
HK (1) HK1222128A1 (hu)
HR (1) HRP20191071T1 (hu)
HU (1) HUE044292T2 (hu)
LT (1) LT2533761T (hu)
PL (2) PL2533761T3 (hu)
PT (2) PT2533761T (hu)
SI (1) SI2533761T1 (hu)
WO (1) WO2011098552A2 (hu)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3004707C (en) 2009-09-02 2022-05-31 Synedgen Inc. Methods and compositions for disrupting biofilm utilizing chitosan-derivative compounds
EP2533761B1 (en) 2010-02-11 2019-03-27 Ablynx N.V. Methods and compositions for the preparation of aerosols
MY163995A (en) 2010-03-12 2017-11-15 Berg Llc Intravenous formulations of coenzyme q10 (coq10) and methods of use thereof
MX369543B (es) * 2011-06-17 2019-11-12 Berg Llc Composiciones farmaceuticas inhalables.
US20150216977A1 (en) * 2012-09-18 2015-08-06 Adocia Stable pharmaceutical composition, comprising an aqueous solution of an antibody-derived therapeutically active protein
JP6603207B2 (ja) 2013-03-15 2019-11-06 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム ヌトリン３ａおよびペプチドを用いた肺線維症の阻害
NL1040254C2 (en) * 2013-05-17 2014-11-24 Ablynx Nv Stable formulations of immunoglobulin single variable domains and uses thereof.
CN115177588A (zh) * 2014-04-03 2022-10-14 瑞士杰特贝林生物制品有限公司 免疫球蛋白的雾化
KR20170094121A (ko) * 2014-09-11 2017-08-17 시너드젠, 인크. 조성물 및 그의 사용 방법
SG11201702688UA (en) * 2014-10-10 2017-04-27 Ablynx Nv Methods of treating rsv infections
TR201909589T4 (tr) * 2014-10-10 2019-07-22 Ablynx Nv Solunum hastalıklarının aerosol terapisinde kullanıma yönelik inhalasyon cihazı.
AU2016225111B2 (en) * 2015-02-27 2021-12-09 Board Of Regents, The University Of Texas System Polypeptide therapeutics and uses thereof
CA3022697A1 (en) 2016-05-02 2017-11-09 Ablynx Nv Treatment of rsv infection
WO2018099968A1 (en) 2016-11-29 2018-06-07 Ablynx N.V. Treatment of infection by respiratory syncytial virus (rsv)
WO2018220234A1 (en) 2017-06-02 2018-12-06 Merck Patent Gmbh Adamts binding immunoglobulins
CA3111563A1 (en) 2018-09-10 2020-03-19 Lung Therapeutics, Inc. Modified peptide fragments of cav-1 protein and the use thereof in the treatment of fibrosis

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2052027T5 (es) 1988-11-11 2005-04-16 Medical Research Council Clonacion de secuencias de dominio variable de inmunoglobulina.
US5945098A (en) * 1990-02-01 1999-08-31 Baxter International Inc. Stable intravenously-administrable immune globulin preparation
US5938117A (en) 1991-04-24 1999-08-17 Aerogen, Inc. Methods and apparatus for dispensing liquids as an atomized spray
ES2322324T3 (es) 1992-08-21 2009-06-19 Vrije Universiteit Brussel Inmumoglobulinas desprovistas de cadenas ligeras.
AU6796094A (en) 1993-04-29 1994-11-21 Raymond Hamers Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of (camelidae)
FR2708622B1 (fr) 1993-08-02 1997-04-18 Raymond Hamers Vecteur recombinant contenant une séquence d'un gène de lipoprotéine de structure pour l'expression de séquences de nucléotides.
US5758637A (en) 1995-08-31 1998-06-02 Aerogen, Inc. Liquid dispensing apparatus and methods
US6085740A (en) 1996-02-21 2000-07-11 Aerogen, Inc. Liquid dispensing apparatus and methods
US5586550A (en) 1995-08-31 1996-12-24 Fluid Propulsion Technologies, Inc. Apparatus and methods for the delivery of therapeutic liquids to the respiratory system
US6205999B1 (en) 1995-04-05 2001-03-27 Aerogen, Inc. Methods and apparatus for storing chemical compounds in a portable inhaler
US6014970A (en) 1998-06-11 2000-01-18 Aerogen, Inc. Methods and apparatus for storing chemical compounds in a portable inhaler
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
AU740043B2 (en) 1996-06-27 2001-10-25 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Recognition molecules interacting specifically with the active site or cleft of a target molecule
EP1027439B1 (en) 1997-10-27 2010-03-17 Bac Ip B.V. Multivalent antigen-binding proteins
WO1999037681A2 (en) 1998-01-26 1999-07-29 Unilever Plc Method for producing antibody fragments
AU3041100A (en) 1999-01-05 2000-07-24 Unilever Plc Binding of antibody fragments to solid supports
ATE276359T1 (de) 1999-01-19 2004-10-15 Unilever Nv Verfahren zur herstellung von antikörperfragmenten
EP1169453A1 (en) 1999-04-22 2002-01-09 Unilever Plc Inhibition of viral infection using monovalent antigen-binding proteins
US6479280B1 (en) 1999-09-24 2002-11-12 Vlaams Interuniversitair Institutuut Voor Biotechnologie Vzw Recombinant phages capable of entering host cells via specific interaction with an artificial receptor
PT1233987E (pt) 1999-11-29 2009-12-28 Bac Ip B V Imobilização de moléculas de ligação ao antigénio de um domínio
US7358096B1 (en) 1999-11-29 2008-04-15 Conopco, Inc. Immobilisation of proteins
EP1134231B1 (en) 2000-03-14 2009-04-15 Unilever N.V. Antibody heavy chain variable domains against human dietary lipases, and their uses
AU2001268855A1 (en) 2000-05-26 2001-12-03 National Research Council Of Canada Single-domain antigen-binding antibody fragments derived from llama antibodies
US20040053340A1 (en) 2000-12-13 2004-03-18 De Haard Johannes Joseph Protein arrays
US20060073141A1 (en) 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
JP4213586B2 (ja) 2001-09-13 2009-01-21 株式会社抗体研究所 ラクダ抗体ライブラリーの作製方法
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
EP1456410A2 (en) 2001-12-11 2004-09-15 AlgoNomics N.V. Method for displaying loops from immunoglobulin domains in different contexts
US20050037358A1 (en) 2001-12-21 2005-02-17 Serge Muyldermans Method for cloning of variable domain sequences
JP2005517674A (ja) 2002-01-03 2005-06-16 フラームス・インテルウニフェルシタイル・インステイチュート・フォール・ビオテヒノロヒー・ヴェーゼットウェー 腫瘍の処置に有用な新規免疫コンジュゲート
US20050271660A1 (en) 2002-09-06 2005-12-08 Alexion Pharmaceuticals, Inc. Nebulization of monoclonal antibodies for treating pulmonary diseases
EP1558650A2 (en) 2002-11-08 2005-08-03 Ablynx N.V. Camelidae antibodies against immunoglobulin e and use thereof for the treatment of allergic disorders
WO2004041862A2 (en) 2002-11-08 2004-05-21 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
WO2005044858A1 (en) 2003-11-07 2005-05-19 Ablynx N.V. Camelidae single domain antibodies vhh directed against epidermal growth factor receptor and uses therefor
ES2542330T3 (es) 2003-01-10 2015-08-04 Ablynx N.V. Polipéptidos terapéuticos, homólogos de los mismos, fragmentos de los mismos y su uso en modular la agregación mediada por plaquetas
US7461263B2 (en) 2003-01-23 2008-12-02 Unspam, Llc. Method and apparatus for a non-revealing do-not-contact list system
CA2535550A1 (en) 2003-08-12 2005-03-03 William M. Yarbrough Treatment for acne vulgaris and method of use
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
BRPI0518151A2 (pt) 2004-10-13 2009-06-16 Ablynx Nv polipetìdeos contra amiloide-beta, ácido nucléico que codifica tal polipetìdeo, composição compreendendo tal polipetìdeo, método para produzir um polipetìdeo e uso do mesmo
EP1844073A1 (en) 2005-01-31 2007-10-17 Ablynx N.V. Method for generating variable domain sequences of heavy chain antibodies
EP2479191A3 (en) 2005-05-18 2013-03-13 Ablynx N.V. Improved nanobodiesTM against tumor necrosis factor-alpha
ES2852423T3 (es) 2005-05-20 2021-09-13 Ablynx Nv NanobodiesTM mejorados para el tratamiento de trastornos mediados por agregación
WO2009074634A2 (en) 2007-12-13 2009-06-18 Glaxo Group Limited Compositions for pulmonary delivery
JP2009523459A (ja) * 2006-01-24 2009-06-25 ドマンティス リミテッド 天然の連結部を含有する融合タンパク質
AU2007224631A1 (en) 2006-03-13 2007-09-20 Ablynx N.V. Amino acid sequences directed against IL-6 and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6-mediated signalling
CA2666599A1 (en) 2006-08-18 2008-02-21 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
EP2069402A2 (en) 2006-09-08 2009-06-17 Ablynx N.V. Serum albumin binding proteins with long half-lives
CA2667466A1 (en) 2006-10-27 2008-05-02 Ablynx N.V. Intranasal delivery of polypeptides and proteins
CA2672595A1 (en) 2006-12-15 2008-06-19 Guy Hermans Amino acid sequences that modulate the interaction between cells of the immune system
US20100062004A1 (en) 2006-12-19 2010-03-11 Ablynx N.V. Amino acid sequences directed against gpcrs and polypeptides comprising the same for the treatment of gpcr-related diseases and disorders
US9156914B2 (en) 2006-12-19 2015-10-13 Ablynx N.V. Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disorders
US20100166734A1 (en) 2006-12-20 2010-07-01 Edward Dolk Oral delivery of polypeptides
EP2097451A2 (en) 2006-12-22 2009-09-09 Ablynx N.V. Anti-chemokine (ccl2, ccl3, ccl5, cxcl11, cxcl12) single-domain antibodies
BRPI0806313A2 (pt) * 2007-01-09 2011-09-06 Wyeth Corp Formulação de anticorpo anti-il-13; formulação em aerossol de um anticorpo anti-il-13; formulaçãoliofilizada de um anticorpo anti-il-13; composição farmacêutica para o tratamento de um transtorno relacionado a il-13; fabricação de uma composição farmacêutica ; método de tratamento de um transtorno relacionado a il-13; seringa injetável; dispositivo para administração nasal; emplastro transdérmico; bolsa intravenosa; kit compreendendo pelo menos um recipiente; kit; e seringa injetável previamente enchida
CA2678218A1 (en) 2007-02-21 2008-08-28 Ablynx N.V. Amino acid sequences directed against vascular endothelial growth factor and polypeptides comprising the same for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization
AU2008252854A1 (en) 2007-05-24 2008-11-27 Ablynx N.V. Amino acid sequences directed against growth factor receptors and polypeptides comprising the same for the treatment of diseases and disorders associated with growth factors and their receptors
CA2687903C (en) 2007-05-24 2016-09-13 Ablynx N.V. Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders
AU2008328779B2 (en) 2007-11-27 2014-06-05 Ablynx N.V. Amino acid sequences directed against HER2 and polypeptides comprising the same for the treatment of cancers and/or tumors
HUE042053T2 (hu) 2008-06-05 2019-06-28 Ablynx Nv Vírus burokfehérjéi elleni aminosav-szekvenciák és az azokat tartalmazó polipeptidek virális betegségek kezelésére
BRPI1010830A2 (pt) 2009-06-05 2023-11-14 Ablynx Nv Sequências de aminoácidos melhoradas direcionadas contra o vírus respiratório sencicial humano (hrsv) e polipetídeos que compreende os mesmos para prevenção e/ou tratamento de infecções do trato respiratório.
EP2473527B1 (en) 2009-09-03 2016-11-30 Ablynx N.V. Stable formulations of polypeptides and uses thereof
EP2533761B1 (en) 2010-02-11 2019-03-27 Ablynx N.V. Methods and compositions for the preparation of aerosols

Also Published As

Publication number Publication date
CA2787718A1 (en) 2011-08-18
US9713589B2 (en) 2017-07-25
PL2533761T3 (pl) 2019-09-30
DK2533761T3 (da) 2019-06-24
EP2533761B1 (en) 2019-03-27
LT2533761T (lt) 2019-07-10
JP5951508B2 (ja) 2016-07-13
US20130019860A1 (en) 2013-01-24
PL3501499T3 (pl) 2023-01-09
PT3501499T (pt) 2022-11-22
US20170333344A1 (en) 2017-11-23
EP3501499A1 (en) 2019-06-26
WO2011098552A3 (en) 2012-03-29
CN105380904A (zh) 2016-03-09
CN102753148A (zh) 2012-10-24
ES2738114T3 (es) 2020-01-20
CA2787718C (en) 2018-05-15
HRP20191071T1 (hr) 2019-09-20
JP7019433B2 (ja) 2022-02-15
EP3501499B1 (en) 2022-09-07
JP2013519654A (ja) 2013-05-30
AU2011214299B2 (en) 2014-07-31
WO2011098552A2 (en) 2011-08-18
SI2533761T1 (sl) 2019-08-30
EP2533761A2 (en) 2012-12-19
ES2931330T3 (es) 2022-12-28
CY1122634T1 (el) 2021-03-12
JP2018083839A (ja) 2018-05-31
CN102753148B (zh) 2018-01-26
JP2016193923A (ja) 2016-11-17
JP6283064B2 (ja) 2018-02-21
PT2533761T (pt) 2019-06-17
US20210346287A1 (en) 2021-11-11
HK1222128A1 (zh) 2017-06-23
US11007146B2 (en) 2021-05-18
AU2011214299A1 (en) 2012-08-02

Similar Documents

Publication Publication Date Title
HK1222128A1 (zh) 用於製備氣霧劑的方法和組合物
IL263729A (en) Preparations and methods for removing biofilms
HK1202071A1 (en) Biocidal compositions and methods of using the same
HK1185796A1 (zh) 包含近端支化化合物的組合物及其製備方法
ZA201402734B (en) Collector compositions and methods of using the same
EP2536756A4 (en) HSA-RELATED COMPOSITIONS AND USE PROCESSES
EP2584897A4 (en) COMPOSITIONS CONTAINING RESVERATROL AND METHODS OF USE
EP2569425A4 (en) ENDORIBONUCLEASE COMPOSITIONS AND METHOD FOR THEIR USE
IL222969A0 (en) Sweetener compositions and methods of preparing the same
GB2507210B (en) Insecticidal compositions and methods of using the same
EP2596112A4 (en) ACETYCYSTEIN COMPOSITIONS AND USE METHOD THEREFOR
EP2582664A4 (en) PHENYL THIOACETATE COMPOUNDS AND COMPOSITIONS AND METHOD FOR THEIR USE
EP2629742A4 (en) HAIR CARE COMPOSITIONS AND RELATED METHODS
EP2552202A4 (en) METHODS AND COMPOSITIONS FOR WEIGHT LOSS
EP2539444A4 (en) COMPOSITIONS AND METHODS FOR THE PRODUCTION OF L-HOMOALANINE
HK1189501A1 (zh) 抗體組合物及使用方法
EP2633047A4 (en) COMPOSITIONS AND METHOD FOR PRODUCING BLOOD PLATES AND USE METHOD THEREFOR
HK1201451A1 (en) Compositions and methods
GB201018650D0 (en) Methods and compositions
HK1254904B (zh) 用於改變xlhed表型的組合物和方法
IL226174A0 (en) Impulse preparations and methods for their preparation
GB201020357D0 (en) Compounds and methods of making the same
GB201002278D0 (en) composition and method of preparation
ZA201209495B (en) Novel methods for the preparation of p2x7r antagonists
HU1000328D0 (en) Nanostuctured indometachine compositions and process for their preparation